Genmab: shares rise after upbeat cervical cancer drug study
(CercleFinance.com) - Shares in Danish biotech firm Genmab are up almost 2% on Tuesday morning after a mid-stage study confirmed that its experimental cervical cancer drug showed good results.
Results from a Phase 2 trial evaluating tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer showed a 24% confirmed objective response rate with a median duration of response of 8.3 months.
The overall response rate is defined as the proportion of patients who have a partial or complete response to therapy.
With these "promising" results, Genmab and its US partner Seattle Genetics said that they plan to discuss them with the Food and Drug Administration.
Genmab shares were up 1.8%, outperforming just a 0.1% rise in the Danish blue-chip OMX index. They have risen by over 39% this year on the back of a promising drug pipeline.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Results from a Phase 2 trial evaluating tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer showed a 24% confirmed objective response rate with a median duration of response of 8.3 months.
The overall response rate is defined as the proportion of patients who have a partial or complete response to therapy.
With these "promising" results, Genmab and its US partner Seattle Genetics said that they plan to discuss them with the Food and Drug Administration.
Genmab shares were up 1.8%, outperforming just a 0.1% rise in the Danish blue-chip OMX index. They have risen by over 39% this year on the back of a promising drug pipeline.
Copyright (c) 2020 CercleFinance.com. All rights reserved.